Literature DB >> 25635489

Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.

Ganesh Raghu1, Moisés Selman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25635489     DOI： 10.1164/rccm.201411-2044ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  47 in total

1.  Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists.

Authors:  Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Transforming growth factor β1 alters the 3'-UTR of mRNA to promote lung fibrosis.

Authors:  Junsuk Ko; Tingting Mills; Jingjing Huang; Ning-Yuan Chen; Tinne C J Mertens; Scott D Collum; Garam Lee; Yu Xiang; Leng Han; Yang Zhou; Chun Geun Lee; Jack A Elias; Soma S K Jyothula; Keshava Rajagopal; Harry Karmouty-Quintana; Michael R Blackburn
Journal:  J Biol Chem       Date:  2019-09-05       Impact factor: 5.157

Review 3.  Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis.

Authors:  Marek Barczyk; Matthias Schmidt; Sabrina Mattoli
Journal:  Stem Cell Rev Rep       Date:  2015-08       Impact factor: 5.739

4.  Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Authors:  P Comeglio; S Filippi; E Sarchielli; A Morelli; I Cellai; C Corno; A Pini; L Adorini; G B Vannelli; M Maggi; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2018-06-19       Impact factor: 4.256

Review 5.  Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices. Disease Modeling and Drug Discovery.

Authors:  Hani N Alsafadi; Franziska E Uhl; Ricardo H Pineda; Kolene E Bailey; Mauricio Rojas; Darcy E Wagner; Melanie Königshoff
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

6.  FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis.

Authors:  Loka R Penke; Jennifer M Speth; Vijaya L Dommeti; Eric S White; Ingrid L Bergin; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

7.  Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.

Authors:  Parid Sava; Anand Ramanathan; Amelia Dobronyi; Xueyan Peng; Huanxing Sun; Adrian Ledesma-Mendoza; Erica L Herzog; Anjelica L Gonzalez
Journal:  JCI Insight       Date:  2017-12-21

8.  Pharmacologic inhibition of lactate production prevents myofibroblast differentiation.

Authors:  Robert Matthew Kottmann; Emma Trawick; Jennifer L Judge; Lindsay A Wahl; Amali P Epa; Kristina M Owens; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-25       Impact factor: 5.464

9.  Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.

Authors:  Eric S White; Meng Xia; Susan Murray; Rachel Dyal; Candace M Flaherty; Kevin R Flaherty; Bethany B Moore; Ling Cheng; Tracy J Doyle; Julian Villalba; Paul F Dellaripa; Ivan O Rosas; Jonathan D Kurtis; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

10.  Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging.

Authors:  Kosuke Kato; Naomi J Logsdon; Yoon-Joo Shin; Sunny Palumbo; Adam Knox; Joseph D Irish; Skye P Rounseville; Sydney R Rummel; Mohamed Mohamed; Kareem Ahmad; Johnny M Trinh; Deepali Kurundkar; Kenneth S Knox; Victor J Thannickal; Louise Hecker
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.